308 related articles for article (PubMed ID: 20546262)
1. A randomized, treat-to-target trial comparing insulin lispro protamine suspension and insulin detemir in insulin-naive patients with Type 2 diabetes.
Fogelfeld L; Dharmalingam M; Robling K; Jones C; Swanson D; Jacober S
Diabet Med; 2010 Feb; 27(2):181-8. PubMed ID: 20546262
[TBL] [Abstract][Full Text] [Related]
2. Comparison of insulin lispro protamine suspension and insulin detemir in basal-bolus therapy in patients with Type 1 diabetes.
Chacra AR; Kipnes M; Ilag LL; Sarwat S; Giaconia J; Chan J;
Diabet Med; 2010 May; 27(5):563-9. PubMed ID: 20536953
[TBL] [Abstract][Full Text] [Related]
3. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
[TBL] [Abstract][Full Text] [Related]
4. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes.
Rosenstock J; Davies M; Home PD; Larsen J; Koenen C; Schernthaner G
Diabetologia; 2008 Mar; 51(3):408-16. PubMed ID: 18204830
[TBL] [Abstract][Full Text] [Related]
5. Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets - the TITRATE study.
Blonde L; Merilainen M; Karwe V; Raskin P;
Diabetes Obes Metab; 2009 Jun; 11(6):623-31. PubMed ID: 19515182
[TBL] [Abstract][Full Text] [Related]
6. Comparison of insulin lispro protamine suspension versus insulin glargine once daily added to oral antihyperglycaemic medications and exenatide in type 2 diabetes: a prospective randomized open-label trial.
Arakaki RF; Blevins TC; Wise JK; Liljenquist DR; Jiang HH; Jacobson JG; Martin SA; Jackson JA
Diabetes Obes Metab; 2014 Jun; 16(6):510-8. PubMed ID: 24298995
[TBL] [Abstract][Full Text] [Related]
7. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.
Hollander P; Cooper J; Bregnhøj J; Pedersen CB
Clin Ther; 2008 Nov; 30(11):1976-87. PubMed ID: 19108786
[TBL] [Abstract][Full Text] [Related]
8. Comparison of insulin lispro protamine suspension versus insulin glargine once daily in basal-bolus therapies with insulin lispro in type 2 diabetes patients: a prospective randomized open-label trial.
Koivisto V; Cleall S; Pontiroli AE; Giugliano D
Diabetes Obes Metab; 2011 Dec; 13(12):1149-57. PubMed ID: 21819517
[TBL] [Abstract][Full Text] [Related]
9. Basal supplementation of insulin lispro protamine suspension versus insulin glargine and detemir for type 2 diabetes: meta-analysis of randomized controlled trials.
Esposito K; Chiodini P; Capuano A; Petrizzo M; Improta MR; Giugliano D
Diabetes Care; 2012 Dec; 35(12):2698-705. PubMed ID: 23173139
[TBL] [Abstract][Full Text] [Related]
10. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen.
Russell-Jones D; Simpson R; Hylleberg B; Draeger E; Bolinder J
Clin Ther; 2004 May; 26(5):724-36. PubMed ID: 15220016
[TBL] [Abstract][Full Text] [Related]
11. Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy.
Malone JK; Kerr LF; Campaigne BN; Sachson RA; Holcombe JH;
Clin Ther; 2004 Dec; 26(12):2034-44. PubMed ID: 15823767
[TBL] [Abstract][Full Text] [Related]
12. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial.
Heller S; Koenen C; Bode B
Clin Ther; 2009 Oct; 31(10):2086-97. PubMed ID: 19922879
[TBL] [Abstract][Full Text] [Related]
13. Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial.
Bartley PC; Bogoev M; Larsen J; Philotheou A
Diabet Med; 2008 Apr; 25(4):442-9. PubMed ID: 18387078
[TBL] [Abstract][Full Text] [Related]
14. Once-daily insulin detemir in a cohort of insulin-naïve patients with type 2 diabetes: a sub-analysis from the PREDICTIVE study.
Meneghini LF; Dornhorst A; Sreenan S;
Curr Med Res Opin; 2009 Apr; 25(4):1029-35. PubMed ID: 19281426
[TBL] [Abstract][Full Text] [Related]
15. Initiating insulin therapy in elderly patients with Type 2 diabetes: efficacy and safety of lispro mix 25 vs. basal insulin combined with oral glucose-lowering agents.
Wolffenbuttel BH; Klaff LJ; Bhushan R; Fahrbach JL; Jiang H; Martin S
Diabet Med; 2009 Nov; 26(11):1147-55. PubMed ID: 19929994
[TBL] [Abstract][Full Text] [Related]
16. Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy.
Fulcher GR; Gilbert RE; Yue DK
Intern Med J; 2005 Sep; 35(9):536-42. PubMed ID: 16105155
[TBL] [Abstract][Full Text] [Related]
17. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes.
Hermansen K; Davies M; Derezinski T; Martinez Ravn G; Clauson P; Home P
Diabetes Care; 2006 Jun; 29(6):1269-74. PubMed ID: 16732007
[TBL] [Abstract][Full Text] [Related]
18. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial.
Bretzel RG; Nuber U; Landgraf W; Owens DR; Bradley C; Linn T
Lancet; 2008 Mar; 371(9618):1073-84. PubMed ID: 18374840
[TBL] [Abstract][Full Text] [Related]
19. Insulin lispro protamine suspension in intensive insulin treatment: an Italian observational study.
Citro G; Lorusso B; Rossi A; Romaniello M; Gentilella R; Cremasco F
Curr Med Res Opin; 2009 Sep; 25(9):2259-65. PubMed ID: 19630489
[TBL] [Abstract][Full Text] [Related]
20. Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.
Ushakova O; Sokolovskaya V; Morozova A; Valeeva F; Zanozina O; Sazonova O; Zhadanova E; Starceva M; Kazakova E; Saifullina M; Shapiro I; Tarasov A; Al-Tayar B; Starkova N
Clin Ther; 2007 Nov; 29(11):2374-84. PubMed ID: 18158078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]